GERON CORP Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
GERON CORP (GERN) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$136.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- GERON CORP effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$36.00K, a 300.00% decline year-over-year.
- GERON CORP effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $18.00K.
- GERON CORP effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$10.00K.
- GERON CORP effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $87.00K.
- GERON CORP effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$12.00K.
- GERON CORP effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$27.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$136.00K 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$36.00K 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $87.00K 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $96.00K 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | $21.00K 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $18.00K 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | -$12.00K 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $17.00K 10-Q · filed 2025-11-07 | |||
| 2024-06-30 | -$31.00K 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | -$10.00K 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$27.00K 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |